LAVAL, Quebec (BUSINESS WIRE) BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellin.
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021 investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.